Total Value in 2013: $13,664M*

Number of Deals in 2013: 248

Company
(Location)

Company
(Location)

Value (M)

Type/Product Area

Terms/Details

Date

AUGUST

Adamis Pharmaceuticals Corp. (San Diego)

3M Co. (St. Paul, Minn.)

ND

Agreement to exclusively license and, with additional payment, fully acquire the Taper Dry Powder Inhaler technology for development of products to treat asthma and chronic obstructive pulmonary disease

Adamis will obtain worldwide rights to use the platform technology in all indications in the dry powder inhalation field

8/7/13

Adimab LLC (Lebanon, N.H.)

Celgene Corp. (Summit, N.J.)

ND

Deal for Adimab to use its technology to identify fully human antibodies against multiple targets

Celgene gains the right to develop and commercialize resulting antibodies, in exchange for an undisclosed up-front payment; for each target, it will have the option to exclusively license antibodies, from which Adimab would receive license fees, clinical milestone payments and royalties

8/21/13

Adimab LLC (Lebanon, N.H.)

Innovent Biologics Inc. (Suzhou, China)

ND

Deal under which Adimab will apply its platform to identify a fully human therapeutic antibody for a target selected by Innovent

Innovent will compensate Adimab for discovery and optimization of therapeutic leads, and Innovent will lead the development efforts; Adimab will reimburse Innovent for certain development costs

8/21/13

Arcturus Therapeutics Inc. (San Diego)

Marina Biotech Inc. (Bothell, Wash.)

ND

Acquisition of patented portfolio of Unlocked Nucleobase Analog intellectual property

Arcturus intends to use the technology in its RNA interference work

8/15/13

Athera Biotechnologies AB (Stockholm)

Medirista AB (Stockholm)

ND

Deal for Athera to transfer rights to the recombinant Annexin A5 product to Medirista

Financial terms were not disclosed

8/26/13

Biomotiv LLC (Cleveland)

Torrey Pines Investment Inc. (San Diego)

ND

Multi-million dollar joint investment framework to fund early stage life science programs and companies over the next seven years

The deal will fund ideas emerging from research institutions with a focus on creating new medicines; the technologies can come from any location worldwide

8/13/13

Ceptaris Therapeutics Inc. (Malvern, Pa.)

Actelion U.S. Holdings Co. (subsidiary of Actelion Ltd.)

$250

Licensing agreement for Valchlor (mechlorethamine gel)

The $250M deal is contingent upon FDA approval of the product

8/1/13

Cytori Therapeutics Inc. (San Diego)

Bimini Technologies (San Diego)

$15

Three-part agreement for the sale of global manufacturing and commercialization rights to its Puregraft product line

Cytori received $5M up front and is entitled to an additional $10M from commercial milestones related to future Puregraft sales; Bimini also acquired global, exclusive rights to commercialize Cytori’s Celution system for alopecia

8/1/13

Imprimis Pharmaceuticals Inc. (San Diego)

Eye Care Northwest and Novel Drug Solutions

ND

Deal in which Imprimis acquired intellectual property, including a provisional patent application, related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and antibacterial agents

The target compound is IPI-140; the acquisition allows Imprimis to pursue the commercial development of certain technologies

8/29/13

Ligand Pharmaceuticals Inc. (San Diego)

Curx Pharmaceuticals Inc. (San Diego)

$21

License agreement to develop and commercialize Ligand’s Captisol-enabled Topiramate Injection for partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate

Ligand is eligible for more than $21M in potential net milestone payments and net royalties on future sales of 6% to 7.5%

8/15/13

Multicell Technologies Inc. (Woonsocket, R.I.)

Genisphere LLC (Hatfield, Pa.)

ND

Collaboration on the development of targeted MCT-485 nanoparticle therapeutics for the treatment of liver cancer

MCT-485 is a noncoding double-stranded micro RNA, which has demonstrated oncolytic and immune-stimulating activity in in vitro models of hepatocellular carcinoma

8/7/13

Novadel Pharma Inc. (Bridgewater, N.J.)

Suda Ltd. (Australia)

$0.4

Novadel sold substantially all of its assets to Suda, including its patents and trademarks related to Novamist, but not including Nitromist or Zolpimist property or licenses

Novadel received $400,000 in cash, 50M shares of Suda common stock and 10M options for purchase of Suda common shares at $0.05 per share

8/15/13

Nuevolution A/S (Copenhagen, Denmark)

Lexicon Pharmaceuticals Inc. (The Woodlands, Texas), Duke University and the Howard Hughes Medical Institute

ND

Collaboration to investigate the biological mechanism of action of an undisclosed G protein-coupled receptor drug target

Nuevolution will provide access to its Chemetics technology for small-molecule drug discovery, and with Lexicon it will provide access to selected chemical libraries created using the technology

8/13/13

Oncobiologics Inc. (Cranbury, N.J.)

Inventiv Health (Somerset, N.J.)

ND

Broad strategic partnership around clinical development for all assets in Oncobiologics’ pipeline

The deal will initially focus on biosimilar assets, though it could be expanded to include innovative molecules; biosimilar assets include copies of Humira, Rituxan, Avastin, Herceptin and Erbitux

8/7/13

Prismic Pharmaceuticals Inc. (Scottsdale, Ariz.)

Epitech Group SRL (Milan, Italy)

ND

Strategic partnership giving Prismic rights to Epitech’s entire product range, including Palmitoylethanolamide for all conditions and, all regulatory categories for inflammatory and pain conditions

Financial details were not disclosed

8/14/13

SEPTEMBER

Abbvie Inc. (Chicago)

Galapagos NV (Mechelen, Belgium)

$405

Global alliance to discover, develop and commercialize potentiator and combination therapies in cystic fibrosis

Abbvie will make an up-front payment of $45M, and Galapagos is eligible to receive another $360M in developmental and regulatory milestone payments, plus sales milestones and double-digit royalty payments

9/25/13

Ablynx NV (Ghent, Belgium)

Abbvie Inc. (Chicago)

$840

Licensing deal for its ALX-0061 nanobody targeted against the cytokine interleukin-6 receptor to treat rheumatoid arthritis and systemic lupus erythematosus

Deal is worth $840M, $175M up front, and $665M in potential milestones up to commercialization, to be followed by double-digit royalties on sales of any products to reach market

9/24/13

Agenus Inc. (Lexington, Mass.)

Vaxlogic LLC (subsidiary of Pharmlogic LLC; Boca Raton, Fla.)

ND

Nonexclusive license agreement for the use of QS-21 Stimulon adjuvant in the development of select addiction, allergy and respiratory disease vaccine candidates

Agenus expects to receive an up-front payment, plus milestones and royalties; Agenus also gets an equity stake in Vaxlogic

9/27/13

Amicus Therapeutics Inc. (Cranbury, N.J.)

Biogen Idec Inc. (Weston, Mass.)

ND

Collaboration to discover, develop and commercialize small molecules to treat Parkinson’s disease

Financial terms were not disclosed, but Amicus is eligible to receive development and regulatory milestones and modest royalties on global net sales

9/11/13

Avidbiotics Corp. (South San Francisco)

Full Spectrum Genetics (South San Francisco)

ND

Research collaboration for the purpose of optimizing multiple therapeutic protein candidates from Avidbiotics’ Micacide protein immune-oncology and antiviral platform

Full Spectrum will receive an up-front payment and is eligible for additional milestones and royalties

9/11/13

Biogen Idec Inc. (Weston, Mass.)

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

$320

Partnership for the discovery and development of therapies for neurological diseases by applying antisense technology

The terms call for $100M up front to Isis, $220M in potential milestones for each antisense candidate and additional funding for clinical trials; the exact amount of milestone payments, license fees and royalty payments to Isis is dependent on the type of molecule advanced by Biogen

9/10/13

Bioheart Inc. (Sunrise, Fla.)

Invitrx Therapeutics Inc. (Irvine, Calif.)

ND

Agreement to license its adipose-derived stem cell products for use in all indications in both human and animal medicine

Terms were not disclosed

9/24/13

Biotime Inc. (Alameda, Calif.)

Jade Therapeutics Inc. (Salt Lake City)

ND

Exclusive sublicense agreement expanding the licensed field of use to include Biotime’s Hystem hydrogel technology for delivery of therapeutic molecules to the human eye

Terms were not disclosed

9/20/13

Canbridge Life Sciences Ltd. (Beijing)

Azaya Therapeutics Inc. (San Antonio)

ND

Deal to develop and commercialize Azaya’s ATI-1123 for treatment of non-small-cell lung cancer and potentially other solid tumor cancer indications in China and North Asia

Canbridge gets exclusive rights to the drug in China, Taiwan and South Korea and will pay Azaya milestones and royalties

9/12/13

Cantab Biopharma-ceuticals Ltd. (Cambridge, UK)

Selcia Ltd. (Ongar, UK)

ND

Drug discovery collaboration to accelerate Cantab’s program to develop improved antibiotics for multidrug-resistant gram-negative bacterial infections based on the polymyxin nucleus

Financial terms were not disclosed

9/4/13

Cell Therapy Catapult Ltd. (London)

Roslin Cells (Edinburgh, UK)

$3.2

Partnership to establish a source of clinical-grade induced pluripotent stem cells banked according to good manufacturing practice in the UK

The establishment of the cell bank with an initial $3.2M investment provides a source of iPS cells acceptable to the regulatory authorities, with the initial six cell lines expected to be available for clinical research in both academia and industry by the end of 2014

9/12/13

Debiopharm Group (Lausanne, Switzerland)

TCG Lifesciences Ltd. (Kolkata, India)

ND

Discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections

Financial terms were not disclosed

9/10/13

Endocyte Inc. (West Lafayette, Ind.)

Nihon Medi-Physics Co. Ltd. (Tokyo)

ND

Agreement to develop and commercialize the companion imaging diagnostic etarfolatide for cancer indications in Japan

Endocyte will receive an initial up-front fee and is eligible for development and regulatory milestones and royalties on sales in Japan

9/9/13

Genentech Inc. (South San Francisco; a unit of the Roche Group)

Arrayit Corp. (Sunnyvale, Calif.)

$0.138

Deal for Genentech to purchase technology to accelerated drug discovery

Genentech paid $138,000 for Arrayit’s Nanoprint LM60 Microarrayer Platform

9/11/13

H3 Biomedicine Inc. (Cambridge, Mass.)

Selvita (Krakow, Poland)

ND

Collaboration to develop cancer drugs, seeking to first validate the druggability of several kinase targets in specific genetic contexts and to then generate multiple candidates

Financial terms were not disclosed

9/17/13

ITM Isotope Technologies Munich AG (Garching, Germany)

Progenics Pharmaceuticals Inc. (Tarrytown, N.Y.)

ND

Agreement for pharmaceutical development and commercialization of radiolabeled DOTA-conjugated somatostatin analogue DOTA-[Tyr3]-octreotide (edotreotide) for human oncology therapeutic use

Terms were not disclosed

9/19/13

Karo Bio AB (Huddinge, Sweden)

4D Science GmbH (Bayern, Germany)

ND

Collaboration to develop treatments for fibrotic diseases based on recent discoveries by Jorg Distler

The deal will focus on generating additional data further validating the nuclear receptor as a target and demonstrating its druggability

9/24/13

Medytox Inc. (Seoul, South Korea)

Allergan Inc. (Irvine, Calif.)

$362

License agreement under which Allergan will pay Medytox an up-front fee of $65M in exchange for exclusive rights, worldwide outside of Korea, to develop and commercialize certain neurotoxin product candidates in development, including a potential liquid-injectable product

Allergan also agreed to make additional contingent payments, including up to an aggregate of $116.5M in development milestones, and up to $180.5M in commercialization milestones, plus royalties

9/27/13

Microconstants China Inc. (Beijing)

Pertinax Therapeutics (Ontario)

ND

Agreement for rights to the Phase II cancer drug, PTX-9908

Microconstants will fund clinical development of PTX-9908 in China, and Pertinax will be entitled to royalties on sales

9/10/13

Scynexis Inc. (Research Triangle Park, N.C.)

R-Pharm (Moscow)

ND

Agreement granting R-Pharm exclusive rights to develop and commercialize Scynexis’ SCY-078 in Russia and several other markets

Scynexis retains rights to the product, an oral glucan synthase inhibitor for systemic fungal diseases, in the Americas, Europe and Asia; it will receive an up-front payment, milestones and royalties

9/11/13

Sernova Corp. (London, Ontario)

Medicyte GmbH (Heidelberg, Germany)

ND

Material transfer agreement to jointly evaluate the use of Medicyte’s upcyte cells in Sernova’s Cell Pouch for the treatment of patients with hemophilia A

Terms were not disclosed

9/11/13

Sigma-Aldrich Corp. (St. Louis)

Horizon Discovery Ltd. (Cambridge, UK)

ND

Nonexclusive license agreement for use of Sigma’s Compozr Zinc Finger Nuclease technology

Terms were not disclosed

9/4/13

Thrombogenics NV (Leuven, Belgium)

Bicycle Therapeutics Ltd. (London)

ND

Collaboration and license agreement to develop and commercialize drugs inhibiting a specific target to treat ophthalmic diseases such as diabetic macular edema

Thrombogenics will pay an up-front fee, development and regulatory milestone payments and royalties

9/6/13

Transcept Pharmaceuticals Inc. (Point Richmond, Calif.)

Shin Nippon Biomedical Laboratories Ltd. (Japan)

$42.5

License agreement to develop and commercialize TO-2070 for acute migraine

Transcept paid $1M up front; development milestones could reach $6.5M and commercial milestones could total up to $35M, making the deal worth up to $42.5M; Transcept also will pay low double-digit royalties

9/26/13

Wilex AG (Munich, Germany)

Nuclea Biotechnologies Inc. (Pittsfield, Mass.)

ND

Development agreement under which Nuclea will develop an automated CAIX IVD IHC assay, known as CAIX Dx

Nuclea will pay development costs for CAIX Dx

9/10/13

OCTOBER

ADC Therapeutics Sarl (Lausanne, Switzerland)

Medimmune (unit of Astrazeneca plc; London)

$40

Collaboration to jointly develop two ADCs that use ADC’s company Spirogen plc’s pyrollobenzodiazepine cytotoxic agents

Medimmune is making a $20M investment in ADC; ADC’s majority owner, Auven Therapeutics Management LLLP, is making a matching $20M to fund the co-development work

10/16/13

Amarantus Bioscience Holdings Inc. (Sunnyvale, Calif.)

Renishaw plc

ND

Letter of intent for the use of Renishaw’s implantable neurosurgical products and systems, including the neuromata sterotactic robot, neuroinspire surgical planning software and neuroinfuse-intraparenchymal delivery system

They will be used for the delivery of MANF in Parkinson’s disease and other neurological conditions

10/4/13

Celgene Corp. (Summit, N.J.)

Pharmakea Therapeutics Inc. (San Diego)

$35

Agreement to develop cancer and fibrotic-disease therapies

The deal is worth $35M

10/7/13

Effimune SAS (Nantes, France)

Janssen Biotech Inc. (unit of Johnson & Johnson; New Brunswick, N.J.)

ND

Global option and license agreement in which Effimune will work with J&J on the development and commercialization of FR104 to treat immune-related disorders

Effimune will grant Janssen an exclusive option to develop FR104 in exchange for undisclosed success-based milestones as well as royalty payments on worldwide net sales

10/4/13

Enteris Biopharma Inc. (Boonton, N.J.)

Keybioscience (subsidiary of Nordic Bioscience A/S; Herlev, Denmark)

ND

Licensing agreement for Enteris’ oral drug delivery and recombinant manufacturing technologies to advance the development of metabolic peptides for Type II diabetes, obesity and other inflammatory conditions

Enteris will license its technologies and become the exclusive provider of preclinical and clinical trial active pharmaceutical ingredient and solid dosage form finished product; Enteris will receive undisclosed fee-for-service revenues and royalties

10/1/13

Evolva Holding SA (Reinach, Switzerland)

Serodus ASA (Oslo, Norway)

ND

Binding term sheet to develop EV-077, Evolva’s compound targeting diabetic nephropathy

Financial terms were not disclosed, but Evolva is entitled to license payments, clinical and regulatory milestones and a single-digit royalty

10/8/13

Geron Corp. (Menlo Park, Calif.)

Biotime Inc. (Alameda, Calif.)

ND

Deal in which Geron divested its human embryonic stem cell assets pursuant to an agreement with Biotime and its subsidiary, Asterias Biotherapeutics Inc.

Asterias received the assets, including a Phase I trial in acute spinal cord injury and Geron’s autologous cellular immunotherapy program; it also assumed liabilities related to those assets

10/2/13

Gnt Biotech and Medicals Corp. (Taiwan)

Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, China)

ND

Exclusive license agreement for the development and commercialization of Chidamide in Taiwan

The product is being evaluated in Phase II trials by Chipscreen Biosciences in peripheral T-cell lymphoma, cutaneous T-cell lymphoma and non-small-cell lung cancer

10/11/13

Horizon Discovery Ltd. (Cambridge, UK)

Blueprint Medicines Corp. (Cambridge, Mass.)

ND

Research service agreement to support Horizon’s discovery platform

Horizon will screen a selection of Blueprint’s highly selective kinase inhibitor tool compounds on a panel of 26 X-MAN isogenic cell lines

10/9/13

Immutep SA (Orsay, France)

Eddingpharm (Hong Kong)

ND

Agreement for development, commercialization and manufacturing of Immutep’s Immufact IMP321

Deal includes milestone payments and royalties; Eddingpharm gains exclusive rights to develop and market IMP321 in mainland China, Hong Kong, Macau and Taiwan

10/8/13

Inform Genomics Inc. (Boston)

Tesaro Inc. (Waltham, Mass.)

ND

Collaboration under which Tesaro will utilize Inform’s bioinformatics and genomic platforms to evaluate the risk of chemotherapy-induced nausea and vomiting

Terms were not disclosed

10/16/13

Kinemed Inc. (Emeryville, Calif.)

Amgen Inc. (Thousand Oaks, Calif.)

ND

Agreement to apply its mass spectrometric dynamic proteomics platform to the study of brain protein homeostasis linked to neurodegenerative diseases

The company’s biomarker platform will allow Amgen to track synthesis and clearance rates of pathogenic proteins in the brain that drive neurodegeneration

10/16/13

Novogen Ltd. (Sydney, Australia)

Genscreen Pty. Ltd. (Victoria, Australia)

ND

Novogen acquired drug technology to develop a class of cancer drugs known as anti-tropomyosins, that target the protein, Tm5NM1

The transaction was based on royalties on product sales upon successful commercialization

10/10/13

Osiris Therapeutics Inc. (Columbia, Md.)

Mesoblast Ltd. (Melbourne, Australia)

$100

Agreement under which Osiris will sell its culture-expanded mesenchymal stem cell business, including Prochymal, to Mesoblast for up to $100M, including up-front and milestone payments

Osiris will receive $50M for closing and delivery of the assets, and is eligible for up to $50M more in clinical and regulatory milestone payments; Mesoblast will assume development costs, and Osiris will receive royalties on any future sales

10/14/13

Sun Pharmaceutical Industries Ltd. (Mumbai, India)

Intrexon Corp. (Germantown, Md.)

ND

Joint venture to develop controllable gene-based therapies to treat ocular diseases that cause partial or total blindness

Both firms will share in the financings of and revenues from the JV

10/2/13

Symphogen A/S (Lyngby, Denmark)

Open Monoclonal Technology Inc. (Palo Alto, Calif.)

ND

Partnership to develop human therapeutic antibodies

Symphogen will contribute its B cell-based antibody identification technology, Symplex, to the collaboration

10/16/13


Notes:

The date indicated refers to the BioWorld Today issue in which the news item can be found.

* The total value represents the amount of disclosed money involving collaborations between biotechnology companies, including manufacturing, marketing and distribution agreements detailed in the following chart.